{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:11:10Z","timestamp":1789690270765,"version":"4.0.1"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472732"],"award-info":[{"award-number":["82472732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["JCHZJL-007"],"award-info":[{"award-number":["JCHZJL-007"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007054","name":"Naval Medical University","doi-asserted-by":"publisher","award":["2023MS0001"],"award-info":[{"award-number":["2023MS0001"]}],"id":[{"id":"10.13039\/501100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2025ZZ2019"],"award-info":[{"award-number":["2025ZZ2019"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Non-coding RNA Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ncrna.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T14:55:32Z","timestamp":1779980132000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics"],"prefix":"10.1016","volume":"20","author":[{"given":"Song","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-2032","authenticated-orcid":false,"given":"Junfeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-5179","authenticated-orcid":false,"given":"Zhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncrna.2026.05.001_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ncrna.2026.05.001_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41568-020-00306-0","article-title":"RNA in cancer","volume":"21","author":"Goodall","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib4","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cells11233776","article-title":"LncRNA\/miRNA\/mRNA network introduces novel biomarkers in prostate cancer","volume":"11","author":"Taheri","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ncrna.2026.05.001_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/15476286.2022.2084839","article-title":"The androgen receptor messenger RNA: what do we know?","volume":"19","author":"Likos","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41420-025-02680-w","article-title":"Emerging implications of N6-methyladenosine in prostate cancer progression and treatment","volume":"11","author":"Xu","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ncrna.2026.05.001_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ncrna.2026.05.001_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","article-title":"Discovery and functional characterization of diverse class 2 CRISPR-cas systems","volume":"60","author":"Shmakov","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.accounts.5c00052","article-title":"Innovative chemical strategies for advanced CRISPR modulation","volume":"58","author":"Liu","year":"2025","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cells13100800","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"13","author":"Laurent","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ncrna.2026.05.001_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymeth.2019.05.023","article-title":"CRISPRi as an efficient tool for gene repression in archaea","volume":"172","author":"Stachler","year":"2020","journal-title":"Methods"},{"key":"10.1016\/j.ncrna.2026.05.001_bib15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.tibtech.2024.02.007","article-title":"CRISPR activation screens: navigating technologies and applications","volume":"42","author":"Clark","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib16","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.cell.2025.02.012","article-title":"Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits","volume":"188","author":"Binan","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300195","article-title":"Progress and perspective of CRISPR-Cas9 technology in translational medicine","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aar6245","article-title":"CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity","volume":"360","author":"Chen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ncrna.2026.05.001_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108047","article-title":"CRISPR-Cas13 technology portfolio and alliance with other genetic tools","volume":"61","author":"Wu","year":"2022","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ncrna.2026.05.001_bib20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00439-017-1792-9","article-title":"RNA splicing and splicing regulator changes in prostate cancer pathology","volume":"136","author":"Munkley","year":"2017","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/biom9040131","article-title":"Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling","volume":"9","author":"Takayama","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.ncrna.2026.05.001_bib22","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.ccell.2023.06.010","article-title":"Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41418-018-0231-3","article-title":"Function, clinical application, and strategies of pre-mRNA splicing in cancer","volume":"26","author":"Di","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ncrna.2026.05.001_bib25","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-18-3965","article-title":"SF3B2-mediated RNA splicing drives human prostate cancer progression","volume":"79","author":"Kawamura","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1158\/1535-7163.MCT-20-0662","article-title":"V-ATPase inhibition decreases mutant androgen receptor activity in castrate-resistant prostate cancer","volume":"20","author":"Whitton","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ncrna.2026.05.001_bib27","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1541-7786.MCR-23-0958","article-title":"Defining splicing factor requirements for androgen receptor variant synthesis in advanced prostate cancer","volume":"22","author":"Walker","year":"2024","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib28","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/jcmm.17849","article-title":"Comprehensively analysis of splicing factors to construct prognosis prediction classifier in prostate cancer","volume":"27","author":"Zhang","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ncrna.2026.05.001_bib29","doi-asserted-by":"crossref","first-page":"E5207","DOI":"10.1073\/pnas.1617467114","article-title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing","volume":"114","author":"Fei","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ncrna.2026.05.001_bib30","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41388-022-02272-3","article-title":"Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer","volume":"41","author":"Wang","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2026.05.001_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00018-022-04175-8","article-title":"Maybe you can turn me on: crispra-based strategies for therapeutic applications","volume":"79","author":"Becirovic","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13578-021-00704-3","article-title":"Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated g\u03b1s-cAMP pathway and AR-YAP1 axis","volume":"11","author":"Kim","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pros.24251","article-title":"AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells","volume":"82","author":"Ikeuchi","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.ncrna.2026.05.001_bib34","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.3390\/ijms23147723","article-title":"Efficient identification of the MYC regulator with the use of the CRISPR library and context-matched database screenings","volume":"23","author":"Tanaka","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib35","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/carcin\/bgab045","article-title":"Small leucine zipper protein promotes the metastasis of castration-resistant prostate cancer through transcriptional regulation of matrix metalloproteinase-13","volume":"42","author":"Kim","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ncrna.2026.05.001_bib36","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1073\/pnas.1920478117","article-title":"Ventral prostate and mammary gland phenotype in mice with complete deletion of the ER\u03b2 gene","volume":"117","author":"Warner","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ncrna.2026.05.001_bib37","first-page":"1","article-title":"Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2026.05.001_bib38","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","article-title":"Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-Targeted therapy via chromatin dysregulation","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112260","article-title":"Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy","volume":"144","author":"Al-mansoori","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ncrna.2026.05.001_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216776","article-title":"CRISPR\/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis","volume":"588","author":"Rodrigo-Faus","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ncrna.2026.05.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06203-2","article-title":"Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ncrna.2026.05.001_bib42","doi-asserted-by":"crossref","first-page":"8550","DOI":"10.1074\/jbc.RA120.013794","article-title":"Androgen attenuates the inactivating phospho\u2013ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity","volume":"295","author":"Cinar","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ncrna.2026.05.001_bib43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.bbagrm.2017.07.005","article-title":"Histone demethylase PHF8 regulates hypoxia signaling through HIF1\u03b1 and H3K4me3","volume":"1860","author":"Maina","year":"2017","journal-title":"Biochim. Biophys. Acta, Gene Regul. Mech."},{"key":"10.1016\/j.ncrna.2026.05.001_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2022.102591","article-title":"p53 alters intracellular Ca2+ signaling through regulation of TRPM4","volume":"104","author":"Kappel","year":"2022","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ncrna.2026.05.001_bib45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/ijms24010502","article-title":"The impact of indoles activating the aryl hydrocarbon receptor on androgen receptor activity in the 22Rv1 prostate cancer cell line","volume":"24","author":"Zgarbov\u00e1","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib46","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3390\/cancers13123009","article-title":"Blockade of HVEM for prostate cancer immunotherapy in humanized mice","volume":"13","author":"Aubert","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ncrna.2026.05.001_bib47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ebiom.2019.06.046","article-title":"TRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancer","volume":"45","author":"Aripaka","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ncrna.2026.05.001_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","article-title":"Role of RNA modifications in cancer","volume":"20","author":"Barbieri","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112840","article-title":"Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3\u2032 untranslated region mutations","volume":"42","author":"Schuster","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib50","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1038\/s41467-024-52472-6","article-title":"A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer","volume":"15","author":"Srinivasan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2026.05.001_bib51","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.1038\/s41467-025-64005-w","article-title":"Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus","volume":"16","author":"Dong","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2026.05.001_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145265","article-title":"Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR\/Cas9 mediated genome editing","volume":"768","author":"Wang","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.ncrna.2026.05.001_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13059-018-1531-0","article-title":"CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops","volume":"19","author":"Guo","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib54","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1039\/D1CS00617G","article-title":"Emerging mRNA technologies: delivery strategies and biomedical applications","volume":"51","author":"Xiao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ncrna.2026.05.001_bib55","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ncrna.2026.05.001_bib56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ncrna.2026.05.001_bib59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12951-025-03607-4","article-title":"Enhancing the potency of 5T4 mRNA vaccine by CD70 mRNA-LNPs through ADCC and T cell boosting in prostate cancer therapy","volume":"23","author":"Cao","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ncrna.2026.05.001_bib61","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s12964-024-01833-1","article-title":"Targeting mRNA-coding genes in prostate cancer using CRISPR\/Cas9 technology with a special focus on androgen receptor signaling","volume":"22","author":"Tabibian","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ncrna.2026.05.001_bib62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtn.2023.06.004","article-title":"Nanoblades allow high-level genome editing in murine and human organoids","volume":"33","author":"Tiroille","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ncrna.2026.05.001_bib63","doi-asserted-by":"crossref","first-page":"46101","DOI":"10.1021\/acsomega.3c07138","article-title":"Design of liposome formulations for CRISPR\/Cas9 enzyme immobilization: evaluation of 5-alpha-reductase enzyme knockout for androgenic disorders","volume":"8","author":"Akbaba","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ncrna.2026.05.001_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.866800","article-title":"Cas13D: a new molecular scissor for transcriptome engineering","volume":"10","author":"Gupta","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib65","doi-asserted-by":"crossref","first-page":"2417605","DOI":"10.1002\/advs.202417605","article-title":"SCORT\u2013Cas13D nanotherapy precisely targets the \u2018undruggable\u2019 transcription factor HoxB13 in metastatic prostate cancer in vivo","volume":"12","author":"Cui","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41388-024-03239-2","article-title":"Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer","volume":"44","author":"Huang","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2026.05.001_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116333","article-title":"Qingdai decoction suppresses prostate cancer growth in lethal-stage prostate cancer models","volume":"308","author":"Chen","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124519","article-title":"DNA aptamer-conjugated lipid nanoparticle for targeted PTEN mRNA delivery to prostate cancer cells","volume":"662","author":"Sam Lee","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ncrna.2026.05.001_bib69","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/pharmaceutics13030380","article-title":"miRNAs as therapeutic tools and biomarkers for prostate cancer","volume":"13","author":"Arrighetti","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ncrna.2026.05.001_bib70","doi-asserted-by":"crossref","first-page":"8561","DOI":"10.1007\/s00210-024-03208-2","article-title":"CRISPR\/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer","volume":"397","author":"Xu","year":"2024","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib71","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ncrna.2026.05.001_bib72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13148-018-0475-2","article-title":"A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97","volume":"10","author":"Ramalho-Carvalho","year":"2018","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib73","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1172\/JCI135373","article-title":"LIN28B promotes the development of neuroendocrine prostate cancer","volume":"130","author":"Lovnicki","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ncrna.2026.05.001_bib74","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41467-018-08153-2","article-title":"LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation","volume":"10","author":"Profumo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2026.05.001_bib75","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41388-022-02289-8","article-title":"The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression","volume":"41","author":"Zhang","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2026.05.001_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914847","article-title":"The effect of gene editing by CRISPR-Cas9 of miR-21 and the indirect target MMP9 in metastatic prostate cancer","volume":"24","author":"Camargo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib77","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-021-01910-0","article-title":"ChrXq27.3 miRNA cluster functions in cancer development","volume":"40","author":"Yoshida","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib78","doi-asserted-by":"crossref","DOI":"10.3791\/63704","article-title":"CRISPR gene editing tool for MicroRNA cluster network analysis","author":"Chambers","year":"2022","journal-title":"JoVE J."},{"key":"10.1016\/j.ncrna.2026.05.001_bib79","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1038\/s41388-019-0760-3","article-title":"MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2026.05.001_bib80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13073-024-01341-4","article-title":"CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines","volume":"16","author":"Merk","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.ncrna.2026.05.001_bib81","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41419-025-08098-7","article-title":"A microRNA CRISPR screen reveals microRNA-483-3p as an apoptotic regulator in prostate cancer cells","volume":"16","author":"Chow","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ncrna.2026.05.001_bib82","first-page":"3777","article-title":"Functional classification of prostate cancer-associated miRNAs through CRISPR\/Cas9-mediated gene knockout","volume":"22","author":"Jiang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-020-01814-5","article-title":"CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p\/miR-449a and E2F5 contributes to prostate carcinogenesis","volume":"40","author":"Qi","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-019-0941-2","article-title":"N-myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway","volume":"18","author":"Yin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13046-022-02293-6","article-title":"Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response","volume":"41","author":"Ashrafizadeh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-98980-3","article-title":"Integrative analysis of blood biomarkers and clinical variables improves early detection of aggressive prostate cancer","volume":"15","author":"Lazareva","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.ncrna.2026.05.001_bib88","doi-asserted-by":"crossref","first-page":"31438","DOI":"10.1021\/acsnano.5c06940","article-title":"Advanced cancer liquid biopsy platform for miRNA detection in extracellular vesicles using CRISPR\/Cas13a and gold nanoarrays","volume":"19","author":"Chen","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.ncrna.2026.05.001_bib89","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1021\/acs.analchem.1c00686","article-title":"CRISPR\/Cas12a-assisted ligation-initiated loop-mediated isothermal amplification (CAL-LAMP) for highly specific detection of microRNAs","volume":"93","author":"Zhang","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ncrna.2026.05.001_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2023.341769","article-title":"A dual amplification-based CRISPR\/Cas12a biosensor for sensitive detection of miRNA in prostate cancer","volume":"1279","author":"Zhu","year":"2023","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.ncrna.2026.05.001_bib91","doi-asserted-by":"crossref","first-page":"13220","DOI":"10.1021\/acs.analchem.3c02231","article-title":"miRNA detection for prostate cancer diagnosis by miRoll-cas: MiRNA rolling circle transcription for CRISPR-cas assay","volume":"95","author":"Ma","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ncrna.2026.05.001_bib92","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1021\/acs.nanolett.4c05829","article-title":"Programmable DNA nanoswitch-regulated plasmonic CRISPR\/Cas12a-gold nanostars reporter platform for nucleic acid and non-nucleic acid biomarker analysis assisted by a spatial confinement effect","volume":"25","author":"Wang","year":"2025","journal-title":"Nano Lett."},{"key":"10.1016\/j.ncrna.2026.05.001_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2022.123784","article-title":"Ultrasensitive visual detection of miRNA-143 using a CRISPR\/Cas12a-based platform coupled with hyperbranched rolling circle amplification","volume":"251","author":"Jiang","year":"2023","journal-title":"Talanta"},{"key":"10.1016\/j.ncrna.2026.05.001_bib94","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.21873\/anticanres.13724","article-title":"MiR-221 is specifically elevated in PC3 cells and its deletion reduces adhesion, motility and growth","volume":"39","author":"Dart","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib95","first-page":"2455","article-title":"Generation of PTEN-knockout (-\/-) murine prostate cancer cells using the CRISPR\/Cas9 system and comprehensive gene expression profiling","volume":"40","author":"Takao","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib96","article-title":"Intercellular delivery of therapeutic oligonucleotides","volume":"72","author":"Valiunas","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1059441","article-title":"State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer","volume":"13","author":"Ramesh","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2021.10.011","article-title":"Circulating RNAs in prostate cancer patients","volume":"524","author":"Mugoni","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ncrna.2026.05.001_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12943-023-01766-2","article-title":"The function and mechanisms of action of circular RNAs in urologic cancer","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7150\/ijbs.52266","article-title":"Advancement and properties of circular RNAs in prostate cancer: an emerging and compelling frontier for discovering","volume":"17","author":"Zhou","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib101","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrg.2016.20","article-title":"Endogenous microRNA sponges: evidence and controversy","volume":"17","author":"Thomson","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib102","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13046-025-03467-8","article-title":"A novel polypeptide encoded by circSPIRE1 promotes prostate cancer proliferation and migration by restraining the ubiquitin-dependent degradation of LRP5","volume":"44","author":"Hu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib103","doi-asserted-by":"crossref","first-page":"136","DOI":"10.21873\/cgp.20494","article-title":"Prostate cancer: De-regulated circular RNAs with efficacy in preclinical in vivo models","volume":"22","author":"Weidle","year":"2025","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.ncrna.2026.05.001_bib104","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ccell.2025.03.027","article-title":"Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation","volume":"43","author":"Teng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib105","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41565-022-01179-0","article-title":"Nanozyme-catalysed CRISPR assay for preamplification-free detection of non-coding RNAs","volume":"17","author":"Broto","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib106","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1568009622666220615154137","article-title":"Genome-wide CRISPR-Cas9 screening and identification of PotentialGenes promoting prostate cancer growth and metastasis","volume":"23","author":"Wang","year":"2023","journal-title":"CCDT"},{"key":"10.1016\/j.ncrna.2026.05.001_bib107","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202009045","article-title":"LNCcation: LncRNA localization and function","volume":"220","author":"Bridges","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-024-01591-0","article-title":"LncRNA-encoded peptides in cancer","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib109","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/cas.13352","article-title":"Long non-coding RNAs and prostate cancer","volume":"108","author":"Misawa","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.eururo.2018.11.012","article-title":"The long noncoding RNA TTTY15, which is located on the Y chromosome, promotes prostate cancer progression by sponging let-7","volume":"76","author":"Xiao","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-020-00894-2","article-title":"PTENP1 is a ceRNA for PTEN: it's CRISPR clear","volume":"13","author":"Vitiello","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib112","first-page":"1","article-title":"Targeting the MALAT1 gene with the CRISPR\/Cas9 technique in prostate cancer","volume":"44","author":"Ahmadi-Balootaki","year":"2022","journal-title":"Gene Environ."},{"key":"10.1016\/j.ncrna.2026.05.001_bib113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302264","article-title":"CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds","volume":"19","author":"Kadry","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ncrna.2026.05.001_bib114","article-title":"SNP rs615552 and lncRNA CDKN2B-AS1 influence brain cancer pathogenesis through multi-omic mechanisms","volume":"15","author":"Ye","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib115","doi-asserted-by":"crossref","first-page":"bbab401","DOI":"10.1093\/bib\/bbab401","article-title":"Comprehensive characterization genetic regulation and chromatin landscape of enhancer-associated long non-coding RNAs and their implication in human cancer","volume":"23","author":"Li","year":"2022","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.ncrna.2026.05.001_bib116","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41588-023-01529-1","article-title":"Systematic differences in discovery of genetic effects on gene expression and complex traits","volume":"55","author":"Mostafavi","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib117","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2018.06.003","article-title":"Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus","volume":"174","author":"Gao","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib118","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2019.04.014","article-title":"Trans effects on gene expression can drive omnigenic inheritance","volume":"177","author":"Liu","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ncrna.2026.05.001_bib119","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/hmg\/ddaa026","article-title":"Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB","volume":"29","author":"Bicak","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib120","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.celrep.2017.10.048","article-title":"A prostate cancer risk element functions as a repressive loop that regulates HOXA13","volume":"21","author":"Luo","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/epi-2016-0134","article-title":"Crucial role of noncoding RNA in driving prostate cancer development and progression","volume":"9","author":"Guo","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.ncrna.2026.05.001_bib122","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1101\/gr.280235.124","article-title":"Cancer driver topologically associated domains identify oncogenic and tumor-suppressive lncRNAs","volume":"35","author":"Rao","year":"2025","journal-title":"Genome Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib123","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jnutbio.2017.01.001","article-title":"Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer","volume":"42","author":"Beaver","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ncrna.2026.05.001_bib124","first-page":"1","article-title":"Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC-3-derived cancer stem cell-like cells through AMPK inhibition, Oncol","volume":"29","author":"Park","year":"2025","journal-title":"Letture"},{"key":"10.1016\/j.ncrna.2026.05.001_bib125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41594-020-0446-0","article-title":"Enhancer RNAs are an important regulatory layer of the epigenome","volume":"27","author":"Sartorelli","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib126","article-title":"Enhancer RNA transcriptome-wide association study reveals a distinctive class of pan-cancer susceptibility eRNAs","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib127","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-025-02170-6","article-title":"Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer","volume":"10","author":"Ma","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ncrna.2026.05.001_bib128","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.7150\/thno.51931","article-title":"Functional roles of antisense enhancer RNA for promoting prostate cancer progression","volume":"11","author":"Pan","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ncrna.2026.05.001_bib129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.celrep.2016.03.038","article-title":"Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer","volume":"15","author":"Zhao","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ncrna.2026.05.001_bib130","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/s41388-018-0128-0","article-title":"HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU\/p300\/EGR1\/HPSE axis","volume":"37","author":"Jiao","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ncrna.2026.05.001_bib131","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1038\/s41467-019-12079-8","article-title":"A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome","volume":"10","author":"Rhie","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2026.05.001_bib132","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1158\/0008-5472.CAN-23-3995","article-title":"CRISPR screening of transcribed super-enhancers identifies drivers of triple-negative breast cancer progression","volume":"84","author":"Lewis","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib133","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1038\/s41467-019-12543-5","article-title":"Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ncrna.2026.05.001_bib134","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1158\/0008-5472.CAN-17-2392","article-title":"Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40779-024-00539-2","article-title":"Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancers","volume":"11","author":"Cai","year":"2024","journal-title":"Milit. Med. Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib136","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41588-025-02128-y","article-title":"The landscape of N6-methyladenosine in localized primary prostate cancer","volume":"57","author":"Xu","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib137","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.7150\/ijbs.75063","article-title":"ELK1-mediated YTHDF1 drives prostate cancer progression by facilitating the translation of polo-like kinase 1 in an m6A dependent manner","volume":"18","author":"Li","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib138","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-020-01267-6","article-title":"YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117366","article-title":"METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3\/AKT pathway and synergizes with PARP inhibitor","volume":"179","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ncrna.2026.05.001_bib140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2022.03.006","article-title":"Targeted manipulation of m6A RNA modification through CRISPR-Cas-based strategies","volume":"203","author":"Sun","year":"2022","journal-title":"Methods"},{"key":"10.1016\/j.ncrna.2026.05.001_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201907301","article-title":"Photoactivatable RNA N6-methyladenosine editing with CRISPR-Cas13","volume":"16","author":"Zhao","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.ncrna.2026.05.001_bib142","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/15476286.2024.2351657","article-title":"Programmable RNA targeting with CRISPR-Cas13","volume":"21","author":"Shi","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib143","doi-asserted-by":"crossref","first-page":"114","DOI":"10.34133\/bmef.0114","article-title":"Application of CRISPR-cas system in human papillomavirus detection using biosensor devices and point-of-care technologies","volume":"6","author":"He","year":"2025","journal-title":"BME Front."},{"key":"10.1016\/j.ncrna.2026.05.001_bib144","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1021\/acs.analchem.4c03206","article-title":"High-sensitivity enzyme-free fluorescence probe based on CRISPR\/Cas13 and the isothermal amplification strategy for axl sensing","volume":"96","author":"Ma","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ncrna.2026.05.001_bib145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.tips.2025.02.009","article-title":"CRISPR\/cas technologies for cancer drug discovery and treatment","volume":"46","author":"Wang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib146","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ncrna.2026.05.001_bib147","doi-asserted-by":"crossref","DOI":"10.17305\/bb.2025.12971","article-title":"Circulating microRNAs in prostate cancer \u2014 non-invasive biomarkers for diagnosis, prognosis and therapy: a review","author":"Volar","year":"2025","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.ncrna.2026.05.001_bib148","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/s12276-024-01310-2","article-title":"Immunoliposome-based targeted delivery of the CRISPR\/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival","volume":"56","author":"Fieni","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ncrna.2026.05.001_bib149","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","article-title":"The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy","volume":"11","author":"Feng","year":"2024","journal-title":"Milit. Med. Res."},{"key":"10.1016\/j.ncrna.2026.05.001_bib150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13073-021-00968-x","article-title":"Deep learning in cancer diagnosis, prognosis and treatment selection","volume":"13","author":"Tran","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.ncrna.2026.05.001_bib151","article-title":"Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ncrna.2026.05.001_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1339189","article-title":"Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics","volume":"11","author":"Lopes","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib153","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-025-09021-y","article-title":"Custom CRISPR\u2013Cas9 PAM variants via scalable engineering and machine learning","volume":"643","author":"Silverstein","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ncrna.2026.05.001_bib154","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jbiotec.2018.08.007","article-title":"Strategies for controlling CRISPR\/Cas9 off-target effects and biological variations in mammalian genome editing experiments","volume":"284","author":"Kimberland","year":"2018","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ncrna.2026.05.001_bib155","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41588-025-02265-4","article-title":"NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling","volume":"57","author":"Lu","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ncrna.2026.05.001_bib156","first-page":"552","article-title":"The contemporary management of prostate cancer","volume":"75","author":"Chakrabarti","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ncrna.2026.05.001_bib157","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.7150\/ijbs.96173","article-title":"PiRNA-4447944 promotes castration-resistant growth and metastasis of prostate cancer by inhibiting NEFH expression through forming the piRNA-4447944-PIWIL2-NEFH complex","volume":"20","author":"Peng","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202402954","article-title":"piRNA PROPER suppresses DUSP1 translation by targeting N6-methyladenosine-mediated RNA circularization to promote oncogenesis of prostate cancer","volume":"11","author":"Ben","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ncrna.2026.05.001_bib159","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/cells11081302","article-title":"MicroRNA-like snoRNA-derived RNAs (sdRNAs) promote castration-resistant prostate cancer","volume":"11","author":"Coley","year":"2022","journal-title":"Cells"}],"container-title":["Non-coding RNA Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468054026000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468054026000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:38:38Z","timestamp":1789688318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468054026000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":159,"alternative-id":["S2468054026000363"],"URL":"https:\/\/doi.org\/10.1016\/j.ncrna.2026.05.001","relation":{},"ISSN":["2468-0540"],"issn-type":[{"value":"2468-0540","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR decodes the RNA regulatory network in prostate cancer: A review from mechanisms to precision therapeutics","name":"articletitle","label":"Article Title"},{"value":"Non-coding RNA Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncrna.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}